Mas Valeria R, Fisher Robert A, Archer Kellie J, Maluf Daniel G
Transplant Molecular Laboratory, Transplant Division, Department of Surgery, Molecular Medicine Research Building, Virginia Commonwealth University, 1220 E. Broad Street, Richmond, VA 23298, USA.
Expert Rev Proteomics. 2009 Aug;6(4):421-31. doi: 10.1586/epr.09.59.
Chronic hepatic disease damages the liver and the resulting wound-healing process might lead to liver fibrosis and subsequent cirrhosis development. Fibrosis is the excessive deposition of extracellular matrix (ECM) in the tissue as consequence of chronic liver damage. The fibrotic response triggers almost all of the complications of end-stage liver disease, including portal hypertension, ascites, encephalopathy, synthetic dysfunction and impaired metabolic capacity. Thus, efforts to understand and attenuate fibrosis have direct clinical implications. Reliable, accurate, disease-specific, noninvasive biomarkers of fibrosis and fibrogenesis in order to prevent or minimize the impact of the chronic liver disease progression are a critical need. This review aims to provide an overview of the possibilities that proteome technology can offer to the knowledge, diagnosis and prognosis of liver fibrosis.
慢性肝病会损害肝脏，而由此产生的伤口愈合过程可能会导致肝纤维化以及随后的肝硬化发展。纤维化是由于慢性肝损伤导致细胞外基质（ECM）在组织中过度沉积。纤维化反应几乎引发了终末期肝病的所有并发症，包括门静脉高压、腹水、脑病、合成功能障碍和代谢能力受损。因此，了解和减轻纤维化的努力具有直接的临床意义。为了预防或最小化慢性肝病进展的影响，迫切需要可靠、准确、针对疾病的非侵入性纤维化和纤维生成生物标志物。本综述旨在概述蛋白质组技术在肝纤维化的知识、诊断和预后方面所能提供的可能性。
